A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.
By S. McGovern, E. Caselli, N. Grigorieff, Brian K. Shoichet. Journal of Medicinal Chemistry, 2002
996 citations recorded by the source corpus.
Subfields: Computational Theory and Mathematics, Molecular Biology, Organic Chemistry
View Paper: https://www.semanticscholar.org/paper/46c176b55633ed47fed73468faa12ee3360080e3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Computational Theory and Mathematics
- J. Wells
- Michelle Arkin
- Yu Chen
- Philip J. Hajduk
- J. Greer
- Brian K. Shoichet
- Jürgen Bajorath
- A. Hopkins
In Molecular Biology
- Michelle Arkin
- J. Wells
- Philip J. Hajduk
- J. Greer
- Jürgen Bajorath
- Yu Chen
- A. Hopkins
- Brian K. Shoichet
In Organic Chemistry
- J. Wells
- Michelle Arkin
- Yu Chen
- J. Greer
- Philip J. Hajduk
- Jürgen Bajorath
- A. Hopkins
- Brian K. Shoichet
Citations in the corpus
- Hit discovery and hit-to-lead approaches. (2006, background): “Such compounds have been pinpointed by repeated biochemical screenings at different protein concentrations or with additives such as detergents [ 19 ].”
- Network pharmacology: the next paradigm in drug discovery. (2008, background): “) that arise from certain small molecules self-associating into colloids at high concentrations in biological buffer”
- A decade of fragment-based drug design: strategic advances and lessons learned (2007, positive): “In addition, false positives can result from the method of detection or mechanisms such as compound aggregatio”
- Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex (2004, background): “…through gene tar- however, raise the possibility of their aggregating in solution, which can generate false positive results in chemical screensgeting or antisense strategies (Green et al., 2001; Kwong et al., 2002) validate the seminal role of -catenin in colon cancer, but (McGovern et al., 2002).”
- Molecular docking and ligand specificity in fragment-based inhibitor discovery (2009, methodology): “01% v/v Triton X-100 to control for aggregation-based artifacts) and monitored at 480 nM wavelength on a Hewlett-Packard HP-8453 spectromete”
- Virtual screening of chemical libraries (2004, background): “Indeed, the two techniques, because of their emphasis on large libraries, share other similarities: both accept limited accuracy in return for screening on a large scale; both look to enrich a list of likely-but-not-certain candidates for further quantitative study; and both are dogged by curious fa”